199 related articles for article (PubMed ID: 29764892)
1. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.
Newton RU; Kenfield SA; Hart NH; Chan JM; Courneya KS; Catto J; Finn SP; Greenwood R; Hughes DC; Mucci L; Plymate SR; Praet SFE; Guinan EM; Van Blarigan EL; Casey O; Buzza M; Gledhill S; Zhang L; Galvão DA; Ryan CJ; Saad F
BMJ Open; 2018 May; 8(5):e022899. PubMed ID: 29764892
[TBL] [Abstract][Full Text] [Related]
2. Weight loss for overweight and obese patients with prostate cancer: a study protocol of a randomised trial comparing clinic-based versus Telehealth delivered EXercise and nutrition intervention (the TelEX trial).
Galvão DA; Taaffe DR; Hayne D; Lopez P; Lyons-Wall P; Tang CI; Chambers SK; Devine A; Spry N; Jeffery E; Kudiarasu C; Joseph D; Newton RU
BMJ Open; 2022 Jun; 12(6):e058899. PubMed ID: 35667725
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of home-based exercise training during adjuvant treatment for metastatic castrate-resistant prostate cancer patients treated with an androgen receptor pathway inhibitor (EXACT).
Brown M; Murphy MH; McAneney H; McBride K; Crawford F; Cole A; O'Sullivan JM; Jain S; Prue G
Support Care Cancer; 2023 Jul; 31(7):442. PubMed ID: 37402060
[TBL] [Abstract][Full Text] [Related]
4. Observational study on time on treatment with abiraterone and enzalutamide.
Fallara G; Lissbrant IF; Styrke J; Montorsi F; Garmo H; Stattin P
PLoS One; 2020; 15(12):e0244462. PubMed ID: 33370378
[TBL] [Abstract][Full Text] [Related]
5. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial.
Connor MJ; Shah TT; Smigielska K; Day E; Sukumar J; Fiorentino F; Sarwar N; Gonzalez M; Falconer A; Klimowska-Nassar N; Evans M; Naismith OF; Thippu Jayaprakash K; Price D; Gayadeen S; Basak D; Horan G; McGrath J; Sheehan D; Kumar M; Ibrahim A; Brock C; Pearson RA; Anyamene N; Heath C; Shergill I; Rai B; Hellawell G; McCracken S; Khoubehi B; Mangar S; Khoo V; Dudderidge T; Staffurth JN; Winkler M; Ahmed HU
BMJ Open; 2021 Feb; 11(2):e042953. PubMed ID: 33632752
[TBL] [Abstract][Full Text] [Related]
6. A comparison of aerobic- and resistance-emphasised exercise on cardiometabolic health and quality of life in men receiving androgen deprivation therapy for prostate cancer: Protocol for a feasibility trial.
Murphy K; Kehoe B; Denieffe S; Hacking D; Fairman CM; Harrison M
Contemp Clin Trials; 2024 Jan; 136():107388. PubMed ID: 37972755
[TBL] [Abstract][Full Text] [Related]
7. Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT.
Alibhai SMH; Ritvo P; Santa Mina D; Sabiston C; Krahn M; Tomlinson G; Matthew A; Lukka H; Warde P; Durbano S; O'Neill M; Culos-Reed SN
BMC Cancer; 2018 Oct; 18(1):1031. PubMed ID: 30352568
[TBL] [Abstract][Full Text] [Related]
8. Supported exercise TrAining for Men wIth prostate caNcer on Androgen deprivation therapy (STAMINA): study protocol for a randomised controlled trial of the clinical and cost-effectiveness of the STAMINA lifestyle intervention compared with optimised usual care, including internal pilot and parallel process evaluation.
McNaught E; Reale S; Bourke L; Brown JE; Collinson M; Day F; Hewison J; Farrin AJ; Ibeggazene S; Innes AQ; Mason E; Meads D; Scope A; Taylor C; Taylor SJ; Turner RR; Rosario DJ;
Trials; 2024 Apr; 25(1):257. PubMed ID: 38610058
[TBL] [Abstract][Full Text] [Related]
9. Randomised phase II trial of stereotactic body radiotherapy in combination with
Spindler NJ; Persson GF; Theile S; Nielsen DL; Høgdall EV; Al-Farra G; Hendel HW; Lorentzen T; Svane IM; Lindberg H; Eefsen RL
BMJ Open; 2023 Jan; 13(1):e063500. PubMed ID: 36717150
[TBL] [Abstract][Full Text] [Related]
10. Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol.
Siltari A; Riikonen J; Koskimäki J; Pakarainen T; Ettala O; Boström P; Seikkula H; Kotsar A; Tammela T; Helminen M; Raittinen PV; Lehtimäki T; Fode M; Østergren P; Borre M; Rannikko A; Marttila T; Salonen A; Ronkainen H; Löffeler S; Murtola TJ
BMJ Open; 2022 Apr; 12(4):e050264. PubMed ID: 35487730
[TBL] [Abstract][Full Text] [Related]
11. Sequences and combinations of multifaceted therapy in advanced prostate cancer.
Vaishampayan UN
Curr Opin Oncol; 2015 May; 27(3):201-8. PubMed ID: 25811344
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).
Harrison MR; Davis PG; Khouri MG; Bartlett DB; Gupta RT; Armstrong AJ; McNamara MA; Zhang T; Anand M; Onyenwoke K; Edwardson S; Craig D; Michalski M; Wu Y; Oyekunle T; Coyne B; Coburn A; Jones LW; George DJ
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):58-64. PubMed ID: 35273377
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study).
Green A; Newton RU; Smith DP; Tuffaha H; Galvão DA; Heathcote P; Patel MI; Christie D; Egger S; Sara SA; Heneka N; Chambers SK; Dunn J
BMJ Open; 2024 Mar; 14(3):e084412. PubMed ID: 38521521
[TBL] [Abstract][Full Text] [Related]
14. Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT).
Brown M; Murphy M; McDermott L; McAneney H; O'Sullivan JM; Jain S; Prue G
Pilot Feasibility Stud; 2019; 5():102. PubMed ID: 31428443
[TBL] [Abstract][Full Text] [Related]
15. The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.
Crippa A; De Laere B; Discacciati A; Larsson B; Connor JT; Gabriel EE; Thellenberg C; Jänes E; Enblad G; Ullen A; Hjälm-Eriksson M; Oldenburg J; Ost P; Lindberg J; Eklund M; Grönberg H
Trials; 2020 Jun; 21(1):579. PubMed ID: 32586393
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and efficacy of a multicomponent exercise medicine programme in patients with pancreatic cancer undergoing neoadjuvant therapy (the EXPAN trial): study protocol of a dual-centre, two-armed phase I randomised controlled trial.
Luo H; Galvão DA; Newton RU; Tang C; Dean A; Jasas K; Johansson M; Yusoff I; Spry N; Taaffe DR
BMJ Open Gastroenterol; 2021 Jun; 8(1):. PubMed ID: 34099463
[TBL] [Abstract][Full Text] [Related]
17. Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol.
Jussila I; Ahtiainen JP; Laakkonen EK; Siltari A; Kaipia A; Jokela T; Kärkkäinen M; Newton R; Raastad T; Huhtala H; Murtola TJ; Seikkula H
BJU Int; 2024 Jul; 134(1):110-118. PubMed ID: 38587276
[TBL] [Abstract][Full Text] [Related]
18. Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study.
Connor MJ; Genie MG; Gonzalez M; Sarwar N; Thippu Jayaprakash K; Horan G; Hosking-Jervis F; Klimowska-Nassar N; Sukumar J; Pokrovska T; Basak D; Robinson A; Beresford M; Rai B; Mangar S; Khoo V; Dudderidge T; Falconer A; Winkler M; Watson V; Ahmed HU
BMJ Open; 2021 Nov; 11(11):e048996. PubMed ID: 34794989
[TBL] [Abstract][Full Text] [Related]
19. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
Labriola MK; Atiq S; Hirshman N; Bitting RL
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):301-309. PubMed ID: 33168966
[TBL] [Abstract][Full Text] [Related]
20. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer.
Kenfield SA; Van Blarigan EL; Panchal N; Bang A; Zhang L; Graff RE; Chen YH; Ryan CJ; Luke A; Newton RU; Tenggara I; Schultz B; Wang E; Lavaki E; Zuniga K; Pinto N; Borno H; Aggarwal R; Friedlander T; Koshkin VS; Harzstark A; Small E; Chan JM
Cancer Med; 2021 Nov; 10(22):8058-8070. PubMed ID: 34636156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
